Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRNX NASDAQ:DAWN NASDAQ:PTGX NASDAQ:SRRK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRNXCrinetics Pharmaceuticals$34.00+0.8%$30.93$24.10▼$62.53$3.20B0.281.07 million shs1.15 million shsDAWNDay One Biopharmaceuticals$7.12-3.4%$6.89$5.64▼$16.76$729.30M-1.25999,873 shs671,274 shsPTGXProtagonist Therapeutics$58.86-1.4%$55.70$33.31▼$61.89$3.66B2.22880,496 shs685,841 shsSRRKScholar Rock$31.67-0.5%$35.11$6.76▼$46.98$3.04B0.361.76 million shs1.26 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRNXCrinetics Pharmaceuticals0.00%-4.52%+10.68%+8.97%-36.80%DAWNDay One Biopharmaceuticals0.00%-5.70%+5.48%+7.23%-49.61%PTGXProtagonist Therapeutics0.00%-2.76%+4.98%+7.68%+25.18%SRRKScholar Rock0.00%+0.83%+0.83%-1.43%+269.54%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRNXCrinetics Pharmaceuticals$34.00+0.8%$30.93$24.10▼$62.53$3.20B0.281.07 million shs1.15 million shsDAWNDay One Biopharmaceuticals$7.12-3.4%$6.89$5.64▼$16.76$729.30M-1.25999,873 shs671,274 shsPTGXProtagonist Therapeutics$58.86-1.4%$55.70$33.31▼$61.89$3.66B2.22880,496 shs685,841 shsSRRKScholar Rock$31.67-0.5%$35.11$6.76▼$46.98$3.04B0.361.76 million shs1.26 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRNXCrinetics Pharmaceuticals0.00%-4.52%+10.68%+8.97%-36.80%DAWNDay One Biopharmaceuticals0.00%-5.70%+5.48%+7.23%-49.61%PTGXProtagonist Therapeutics0.00%-2.76%+4.98%+7.68%+25.18%SRRKScholar Rock0.00%+0.83%+0.83%-1.43%+269.54%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRNXCrinetics Pharmaceuticals 2.78Moderate Buy$68.86102.52% UpsideDAWNDay One Biopharmaceuticals 3.13Buy$25.29255.14% UpsidePTGXProtagonist Therapeutics 3.09Buy$67.7315.07% UpsideSRRKScholar Rock 3.20Buy$45.7544.46% UpsideCurrent Analyst Ratings BreakdownLatest DAWN, CRNX, SRRK, and PTGX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/12/2025PTGXProtagonist TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/12/2025PTGXProtagonist TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$73.008/21/2025SRRKScholar RockJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$50.008/18/2025DAWNDay One BiopharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$25.008/11/2025CRNXCrinetics PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$90.00 ➝ $86.008/7/2025PTGXProtagonist TherapeuticsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform8/7/2025PTGXProtagonist TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$67.00 ➝ $69.008/7/2025SRRKScholar RockBMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$57.00 ➝ $45.008/6/2025DAWNDay One BiopharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$18.00 ➝ $16.008/6/2025DAWNDay One BiopharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$36.00 ➝ $25.007/30/2025SRRKScholar RockRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetStrong-Buy$53.00(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRNXCrinetics Pharmaceuticals$1.04M3,078.96N/AN/A$14.29 per share2.38DAWNDay One Biopharmaceuticals$131.16M5.56N/AN/A$4.99 per share1.43PTGXProtagonist Therapeutics$434.43M8.43$4.52 per share13.03$11.33 per share5.20SRRKScholar Rock$33.19M91.73N/AN/A$3.94 per share8.04Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRNXCrinetics Pharmaceuticals-$298.41M-$4.11N/AN/AN/AN/A-32.28%-29.45%11/11/2025 (Estimated)DAWNDay One Biopharmaceuticals-$95.50M-$0.95N/AN/AN/A-50.63%-19.01%-16.99%10/29/2025 (Estimated)PTGXProtagonist Therapeutics$275.19M$0.7084.09N/AN/A24.88%8.12%7.41%11/6/2025 (Estimated)SRRKScholar Rock-$246.29M-$2.91N/AN/AN/AN/A-127.11%-90.09%11/11/2025 (Estimated)Latest DAWN, CRNX, SRRK, and PTGX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025CRNXCrinetics Pharmaceuticals-$1.13-$1.23-$0.10-$1.23$0.52 million$1.03 million8/6/2025Q2 2025PTGXProtagonist Therapeutics-$0.53-$0.55-$0.02-$0.55$8.32 million$5.55 million8/6/2025Q2 2025SRRKScholar Rock-$0.66-$0.98-$0.32-$0.98$0.11 millionN/A8/5/2025Q2 2025DAWNDay One Biopharmaceuticals-$0.35-$0.29+$0.06-$0.29$35.55 million$33.91 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRNXCrinetics PharmaceuticalsN/AN/AN/AN/AN/ADAWNDay One BiopharmaceuticalsN/AN/AN/AN/AN/APTGXProtagonist TherapeuticsN/AN/AN/AN/AN/ASRRKScholar RockN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRNXCrinetics PharmaceuticalsN/A17.8017.80DAWNDay One BiopharmaceuticalsN/A9.659.53PTGXProtagonist TherapeuticsN/A16.9716.97SRRKScholar Rock0.216.336.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRNXCrinetics Pharmaceuticals98.51%DAWNDay One Biopharmaceuticals87.95%PTGXProtagonist Therapeutics98.63%SRRKScholar Rock91.08%Insider OwnershipCompanyInsider OwnershipCRNXCrinetics Pharmaceuticals6.00%DAWNDay One Biopharmaceuticals6.20%PTGXProtagonist Therapeutics4.90%SRRKScholar Rock13.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRNXCrinetics Pharmaceuticals21094.18 million88.53 millionOptionableDAWNDay One Biopharmaceuticals60102.43 million96.08 millionOptionablePTGXProtagonist Therapeutics12062.21 million59.16 millionOptionableSRRKScholar Rock14096.13 million83.34 millionOptionableDAWN, CRNX, SRRK, and PTGX HeadlinesRecent News About These CompaniesJones Financial Companies Lllp Purchases New Stake in Scholar Rock Holding Corporation $SRRK5 hours ago | marketbeat.comDynamic Technology Lab Private Ltd Acquires Shares of 14,240 Scholar Rock Holding Corporation $SRRKSeptember 14 at 3:44 AM | marketbeat.comScholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 12 at 4:15 PM | businesswire.comWoodline Partners LP Has $27.66 Million Stock Holdings in Scholar Rock Holding Corporation $SRRKSeptember 12 at 6:41 AM | marketbeat.comOctagon Capital Advisors LP Sells 159,000 Shares of Scholar Rock Holding Corporation $SRRKSeptember 11, 2025 | marketbeat.comCan Apitegromab Approval Turn Scholar Rock (SRRK) Into the Next Biotech Multibagger?September 11, 2025 | insidermonkey.comPolar Asset Management Partners Inc. Sells 12,426 Shares of Scholar Rock Holding Corporation $SRRKSeptember 9, 2025 | marketbeat.comGraham Capital Management L.P. Buys New Stake in Scholar Rock Holding Corporation $SRRKSeptember 8, 2025 | marketbeat.comScholar Rock Holding Corporation $SRRK Shares Sold by Trexquant Investment LPSeptember 7, 2025 | marketbeat.comBrokerages Set Scholar Rock Holding Corporation (NASDAQ:SRRK) Target Price at $45.75September 7, 2025 | americanbankingnews.comAdage Capital Partners GP L.L.C. Has $64.88 Million Holdings in Scholar Rock Holding Corporation $SRRKSeptember 5, 2025 | marketbeat.comScholar Rock Holding Corporation (NASDAQ:SRRK) Receives Consensus Rating of "Buy" from AnalystsSeptember 5, 2025 | marketbeat.comScholar Rock Holding Corporation $SRRK Shares Bought by ADAR1 Capital Management LLCSeptember 4, 2025 | marketbeat.comRedmile Group LLC Sells 151,600 Shares of Scholar Rock Holding Corporation $SRRKSeptember 4, 2025 | marketbeat.comVestal Point Capital LP Takes Position in Scholar Rock Holding Corporation $SRRKSeptember 4, 2025 | marketbeat.comScholar Rock Holding Corporation $SRRK Shares Acquired by Birchview Capital LPSeptember 4, 2025 | marketbeat.comRA Capital Management L.P. Increases Stock Holdings in Scholar Rock Holding Corporation $SRRKSeptember 4, 2025 | marketbeat.comScholar Rock Holding Corporation $SRRK Shares Acquired by Northern Trust CorpSeptember 2, 2025 | marketbeat.comInvesco Ltd. Sells 257,224 Shares of Scholar Rock Holding Corporation $SRRKSeptember 2, 2025 | marketbeat.comRafferty Asset Management LLC Boosts Stake in Scholar Rock Holding Corporation $SRRKSeptember 1, 2025 | marketbeat.comPrice T Rowe Associates Inc. MD Sells 389,535 Shares of Scholar Rock Holding Corporation $SRRKAugust 26, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDAWN, CRNX, SRRK, and PTGX Company DescriptionsCrinetics Pharmaceuticals NASDAQ:CRNX$34.00 +0.27 (+0.80%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$34.25 +0.25 (+0.74%) As of 08:04 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.Day One Biopharmaceuticals NASDAQ:DAWN$7.12 -0.25 (-3.39%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$7.08 -0.04 (-0.63%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.Protagonist Therapeutics NASDAQ:PTGX$58.86 -0.82 (-1.37%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$60.54 +1.69 (+2.86%) As of 08:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.Scholar Rock NASDAQ:SRRK$31.67 -0.17 (-0.53%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$32.70 +1.03 (+3.25%) As of 08:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Wall Street Eyes +30% Upside in Synopsys After Huge Earnings Fall Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Football Season Is Here and DraftKings Stock Is Surging RH Stock Slides After Mixed Earnings and Tariff Concerns Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
